VERMOX (mebendazole) chewable tablets, 100 mg – Highlights of Prescribing Information (NDA 017481) (2017)

Government Record · Janssen Pharmaceuticals, Inc. (label approved by the U.S. Food and Drug Administration) · June 14, 2017

Janssen Pharmaceuticals et al., 2017-06-14: An FDA-approved label for the original 100 mg chewable Vermox, stating 'Initial U.S. Approval: 1974' and listing the five intestinal worm indications.

VERMOX(TM) is an anthelmintic indicated for the treatment of patients two years of age and older with gastrointestinal infections caused by: Ancylostoma duodenale (hookworm), Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm), Necator americanus (hookworm), and Trichuris trichiura (whipworm)

p. 1

Janssen Pharmaceuticals et al., 2017-06-14: An FDA-approved label for the original 100 mg chewable Vermox, stating 'Initial U.S. Approval: 1974' and listing the five intestinal worm indications. Federal label record. NDA 017481, sponsor Janssen Pharmaceuticals; original approval 1974-06-28 (openFDA Drugs@FDA record, see MBA-10); product marketing status per FDA: Discontinued, with the FDA annotation that the product was not withdrawn for safety or effectiveness reasons. Label revision date on the document: 2017 (submission 017481s047, 2017-06-14). Dose on this label for adults and children >=2 years is 1 tablet (100 mg) per indication schedule; recorded as published, not recommended here. Context: FDA lists this product as discontinued (MBA-10). Also filed as MBD-02 (claims C1, C3).